Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus

Denali Therapeutics (DNLI) reported a fourth-quarter 2024 loss of 67 cents per share, narrower than the Zacks Consensus Estimate of a loss of 83 cents. The company reported a loss of 86 cents in the year-ago quarter.The loss per share improved year over year due to a decline in total operating expenses and an increase in the number of shares outstanding.In the absence of a marketed product, the company only recognizes revenues from ongoing collaborations. Denali did not generate collaboration revenues in th ...